BCM
MRKR icon

BlueCrest Capital Management’s Marker Therapeutics MRKR Stock Holding History

BlueCrest Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,300
Closed -$350K – 822
2019
Q1 		$350K Buy
+5,300
New +$309K 0.01% 630

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlueCrest Capital Management's MRKR Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Marker Therapeutics (MRKR) in Q2 2019, closing a stake of 5,300 shares — an estimated $350K sold.

BlueCrest Capital Management first reported a position in MRKR in Q1 2019 and held it in 1 quarter. The position peaked at $350K in Q1 2019. 70 funds tracked by Wall St. Rank hold MRKR as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Marker Therapeutics position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 5,300 Marker Therapeutics shares in Q2 2019, an estimated $350K.
  • BlueCrest Capital Management first reported a position in Marker Therapeutics in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Marker Therapeutics position peaked at $350K in Q1 2019.
  • 70 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.